ClinicalTrials.gg
RecruitingNCT07496372REVIVE-HEARTUpdated May 12, 2026

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

A Phase 3 interventional study of HiCM-188 therapy and CABG surgery in Heart Failure, sponsored by HELP Therapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by HELP Therapeutics Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
163rd of 246
80 · median 127
Started
2026
with 41 others
Phase 3
41 of 375
16 open now
Primary completion
2027-06
later than 115 of 181 live
Registered
337th of 375
by date

Among the 375 studies in Heart Failure with a site in China, this one is the 163rd largest by planned enrollment of the 246 interventional ones that give a count, is one of 42 that started in 2026, is one of 41 in phase 3, reaches primary completion later than 115 of the 181 other live ones, and was the 337th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

156 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)

Read the detailed description

REVIVE-HEART is a multicenter, randomized, controlled, confirmatory clinical trial evaluating patients with advanced heart failure (NYHA III-IV). Participants were assigned to receive either conventional coronary artery bypass grafting (CABG) alone or CABG combined with HiCM-188 (150 million cells). The cells were administered via myocardial injections around the infarcted area, followed by postoperative immunosuppressive therapy. Efficacy and safety were assessed 12 months post-treatment.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Advanced heart failure
  • HiCM188
  • HiCM-188
  • REVIVE-HEART
  • cardiomyocyte
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 75 years, regardless of gender;
  2. Patients with ischemic heart failure with functional class III or IV after receiving the maximum tolerated dose of guideline-directed medical therapy (GDMT);
  3. ≤ 35% as measured by cardiac MRI;
  4. Coronary angiography meeting the indications for coronary artery bypass grafting (CABG) surgery;
  5. Voluntary participation and signing of the form.

Exclusion criteria

Exclusion Criteria:

Patients considered for this trial must not meet any of the following criteria:

  1. Acute viral myocarditis;
  2. Acute phase of myocardial infarction (≤ 3 months);
  3. Cardiac amyloidosis;
  4. Pericarditis;
  5. Expected to undergo heart transplantation;
  6. Suffering from a disease that restricts the motor system, making them unable to complete the 6-minute walk test;
  7. Suffering from diseases;
  8. Estimated (eGFR) \< 35 ml/min/1.73m², or (AST) and alanine aminotransferase (ALT) > 100 U/L;
  9. Presence of any untreated precancerous lesions or those requiring active monitoring;
  10. Occurrence of malignant tumors within 5 years prior to screening;
  11. Expected to undergo other concurrent cardiac surgeries (excluding ventricular aneurysm resection and left atrial appendage excision/ligation);
  12. Having to the use of ;
  13. Having contraindications to MRI;
  14. Having contraindications to CABG surgery;
  15. Females who are pregnant, lactating, or have a positive blood pregnancy test;
  16. Plans to conceive within one year;
  17. Having systemic diseases that are not effectively controlled;
  18. Other conditions deemed unsuitable for participation in this clinical trial as evaluated by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Control group

    Coronary artery bypass grafting surgery

    Procedure: CABG surgery

  • Experimental
    Experimental group

    Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) during coronary artery bypass grafting surgery

    Biological: HiCM-188 therapy · Procedure: CABG surgery

Interventions

  • Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) during coronary artery bypass grafting surgery

  • ProcedureCABG surgery

    Conventional coronary artery bypass grafting (CABG) surgery

06

What researchers measure

Primary outcomes

  1. 6-minute walk distance (6MWD)

    Time frame: 12 months after surgery

Secondary outcomes

  1. All-cause mortality and cardiovascular mortality

    Time frame: 12 months after surgery

  2. 6MWD

    Time frame: 6 months after surgery

  3. Change from baseline in the NYHA classification

    Time frame: 12 months after surgery

  4. Worsening heart failure (including events requiring hospitalization or emergency treatment due to worsening symptoms and signs of heart failure)

    Time frame: 12 months after surgery

  5. Change from baseline in the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    The MLHFQ is a self-administered disease-specific outcome measure instrument for patients with heart failure (HF), comprising 21 items rated on Likert scales, representing different degrees of impact of HF on QoL. The MLHFQ scores are on a range of 0-105, in which lower scores reflect better health status.

    Time frame: 12 months after surgery

  6. Change from baseline in the SF-36 questionnaire

    The 36-Item Short Form Survey(SF-36) is a self-administered outcome measure instrument that comprises 36 items grouped into 8 dimensions: limitations in physical activities because of health problems, limitations in social activities because of physical or emotional problems, limitations in usual role activities because of physical health problems, bodily pain, general mental health, limitations in usual role activities because of emotional problems, vitality, general health perceptions. The SF-36 scores are on a range of 0-100, in which higher scores reflect better health status.

    Time frame: 12 months after surgery

  7. Myocardial blood flow as assessed by SPECT

    Time frame: 12 months after surgery

  8. Myocardial viability as assessed by SPECT

    Time frame: 12 months after surgery

  9. Left ventricular ejection fraction as assessed by MRI

    Left ventricular ejection fraction

    Time frame: 12 months after surgery

  10. Cardiac Volumes as assessed by MRI

    Left ventricular end-diastolic volume index (LVEDVi), Left ventricular end-systolic volume index (LVESVi) and Stroke Volume (SV)

    Time frame: 12 months after surgery

  11. Scar size as assessed by MRI

    Time frame: 12 months after surgery

  12. Change from baseline in NT-proBNP level

    Time frame: 12 months after surgery

  13. Tumor markers abnormally elevated compared to baseline

    Time frame: 12 months after surgery

  14. Other AEs

    Time frame: 12 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jun 2027, 14 months later.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 14 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 27, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07496372
Lead sponsor
HELP Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HICM-188

Start the discussion